CL2021002307A1 - Uso de virus oncolíticos para el tratamiento del cáncer - Google Patents
Uso de virus oncolíticos para el tratamiento del cáncerInfo
- Publication number
- CL2021002307A1 CL2021002307A1 CL2021002307A CL2021002307A CL2021002307A1 CL 2021002307 A1 CL2021002307 A1 CL 2021002307A1 CL 2021002307 A CL2021002307 A CL 2021002307A CL 2021002307 A CL2021002307 A CL 2021002307A CL 2021002307 A1 CL2021002307 A1 CL 2021002307A1
- Authority
- CL
- Chile
- Prior art keywords
- oncolytic viruses
- cancer treatment
- viruses
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al uso de virus oncolíticos (por ejemplo, virus HSV-1 modificados) para el tratamiento de diversos tipos de cáncer. Además, la presente invención se refiere a composiciones y kits relacionados con dichos usos de virus oncolíticos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813961P | 2019-03-05 | 2019-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002307A1 true CL2021002307A1 (es) | 2022-05-27 |
Family
ID=70289836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002307A CL2021002307A1 (es) | 2019-03-05 | 2021-09-03 | Uso de virus oncolíticos para el tratamiento del cáncer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220090133A1 (es) |
EP (1) | EP3935182A1 (es) |
JP (1) | JP2022522817A (es) |
KR (1) | KR20210135532A (es) |
CN (1) | CN113439123A (es) |
AR (1) | AR120048A1 (es) |
AU (1) | AU2020232264A1 (es) |
BR (1) | BR112021017551A2 (es) |
CA (1) | CA3131529A1 (es) |
CL (1) | CL2021002307A1 (es) |
EA (1) | EA202192420A1 (es) |
IL (1) | IL285221A (es) |
MX (1) | MX2021010458A (es) |
SG (1) | SG11202108449SA (es) |
TW (1) | TW202100542A (es) |
UY (1) | UY38603A (es) |
WO (1) | WO2020180864A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022204434A1 (en) * | 2021-03-24 | 2022-09-29 | Virogin Biotech Canada Ltd | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EP1141338A4 (en) | 1998-12-31 | 2002-09-25 | Arch Dev Corp | RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES |
AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
GB0001475D0 (en) * | 2000-01-21 | 2000-03-15 | Neurovex Ltd | Virus strains |
KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
AU2002306919B2 (en) | 2001-03-27 | 2007-11-22 | Tomoki Todo | Viral vectors and their use in therapeutic methods |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
EP3929216A1 (en) | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US20130028882A1 (en) | 2011-07-07 | 2013-01-31 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
PL2753355T3 (pl) | 2011-09-08 | 2019-04-30 | Benevir Biopharm Inc | Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze |
EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
JP7200104B2 (ja) | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
JOP20190256A1 (ar) * | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
JP7249323B2 (ja) * | 2017-07-26 | 2023-03-30 | オンコラス, インコーポレイテッド | 腫瘍溶解性ウイルスベクター及びその使用 |
MA49849A (fr) * | 2017-08-07 | 2020-06-17 | Amgen Inc | Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique |
US11802292B2 (en) * | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
CN108315351B (zh) * | 2018-04-12 | 2022-03-22 | 济南海湾生物工程有限公司 | 一种用于工业生产的哺乳动物细胞表达载体 |
CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
KR20210080375A (ko) * | 2018-09-15 | 2021-06-30 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한 재조합 폭스바이러스 |
-
2020
- 2020-03-03 KR KR1020217030518A patent/KR20210135532A/ko unknown
- 2020-03-03 EP EP20719515.7A patent/EP3935182A1/en active Pending
- 2020-03-03 WO PCT/US2020/020793 patent/WO2020180864A1/en active Application Filing
- 2020-03-03 CA CA3131529A patent/CA3131529A1/en active Pending
- 2020-03-03 AU AU2020232264A patent/AU2020232264A1/en active Pending
- 2020-03-03 EA EA202192420A patent/EA202192420A1/ru unknown
- 2020-03-03 SG SG11202108449SA patent/SG11202108449SA/en unknown
- 2020-03-03 BR BR112021017551A patent/BR112021017551A2/pt unknown
- 2020-03-03 US US17/435,768 patent/US20220090133A1/en active Pending
- 2020-03-03 JP JP2021551929A patent/JP2022522817A/ja active Pending
- 2020-03-03 MX MX2021010458A patent/MX2021010458A/es unknown
- 2020-03-03 CN CN202080014516.5A patent/CN113439123A/zh active Pending
- 2020-03-05 AR ARP200100619A patent/AR120048A1/es unknown
- 2020-03-05 TW TW109107309A patent/TW202100542A/zh unknown
- 2020-03-05 UY UY0001038603A patent/UY38603A/es unknown
-
2021
- 2021-07-29 IL IL285221A patent/IL285221A/en unknown
- 2021-09-03 CL CL2021002307A patent/CL2021002307A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202100542A (zh) | 2021-01-01 |
UY38603A (es) | 2020-08-31 |
AR120048A1 (es) | 2022-02-02 |
CN113439123A (zh) | 2021-09-24 |
EA202192420A1 (ru) | 2021-12-13 |
CA3131529A1 (en) | 2020-09-10 |
MX2021010458A (es) | 2021-09-21 |
IL285221A (en) | 2021-09-30 |
JP2022522817A (ja) | 2022-04-20 |
BR112021017551A2 (pt) | 2021-11-09 |
AU2020232264A1 (en) | 2021-08-26 |
US20220090133A1 (en) | 2022-03-24 |
KR20210135532A (ko) | 2021-11-15 |
SG11202108449SA (en) | 2021-09-29 |
EP3935182A1 (en) | 2022-01-12 |
WO2020180864A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001719A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
BR112018071678A2 (pt) | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv | |
CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
CO2018013738A2 (es) | Novedosos virus vaccinia modificados genéticamente | |
BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
GT201300093A (es) | Compuestos antivirales | |
BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
CL2018003383A1 (es) | Proteínas f de prefusión del vrs estabilizadas. | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
EA202190974A1 (ru) | Противовирусные пролекарства и их наносоставы | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
CL2021002307A1 (es) | Uso de virus oncolíticos para el tratamiento del cáncer | |
BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
BR112022001881A2 (pt) | Vírus vaccinia oncolítico geneticamente manipulado e métodos de usos do mesmo | |
MX2022016281A (es) | Composiciones y metodos antivirales de amplio espectro. |